Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011
by Hanscom, Thomas, M.D..
Recruitment status was Recruiting
Study NCT01471691 Information provided by Hanscom, Thomas, M.D.
First Received on November 9, 2011. Last Updated on November 10, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Branch Retinal Vein Occlusion
Central Retinal Vein Occlusion
Additional conditions recognized in this trial
Retinal Vein Occlusion
More general conditions related to this trial
Embolism and Thrombosis
Signs and Symptoms
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Angiogenesis Modulating Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Hanscom, Thomas, M.D.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers